MCID: DXR001
MIFTS: 37

Doxorubicin Induced Cardiomyopathy malady

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

About this section

Aliases & Descriptions for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 48

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

About this section
MalaCards based summary: Doxorubicin Induced Cardiomyopathy is related to cardiomyopathy and hypogonadotropic hypogonadism 16 with or without anosmia. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways are Physiological and Pathological Hypertrophy of the Heart and G-protein signaling_K-RAS regulation pathway. Affiliated tissues include heart, bone and bone marrow, and related mouse phenotypes are Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation and Decreased substrate adherent cell growth.

Related Diseases for Doxorubicin Induced Cardiomyopathy

About this section

Graphical network of diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to doxorubicin induced cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

About this section

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00206-A10.2MAPK14, MET
2GR00193-A-310.0EGFR, EPHB2, MAPK14
3GR00230-A-19.7EGFR, MAPK14, MET
4GR00055-A-19.4EGFR, EPHB2, MAPK14, MET

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

41 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.8CNR1, EGFR, EPOR, GATA4, HGF, MET
2MP:00053818.7CNR1, ECE1, EGFR, EPHB2, GATA4, MET
3MP:00053708.7EGFR, EPOR, GATA4, HGF, MAPK14, MET
4MP:00053698.6DES, ECE1, EGFR, GATA4, MAPK14, MET
5MP:00107718.4CNR1, CSF3, ECE1, EGFR, GATA4, MAPK14
6MP:00053808.2ECE1, EGFR, EPOR, GATA4, HGF, MAPK14
7MP:00053978.0CSF3, ECE1, EGFR, EPOR, GATA4, HGF
8MP:00053857.9DES, ECE1, EGFR, EPOR, GATA4, HGF
9MP:00053847.7CNR1, DES, EGFR, EPHB2, EPOR, GATA4
10MP:00036317.7CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
11MP:00053787.5CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
12MP:00028737.3CNR1, ECE1, EGFR, EPOR, GATA4, MAPK14
13MP:00107687.1CNR1, DES, ECE1, EGFR, EPHB2, EPOR

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

About this section

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 2, Phase 3175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
DoxilApproved June 1999Phase 2, Phase 3175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
3Anti-Bacterial AgentsPhase 2, Phase 311226
4Topoisomerase InhibitorsPhase 2, Phase 35069
5Antibiotics, AntitubercularPhase 2, Phase 37180
6
Cyclophosphamideapproved, investigationalPhase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
Paclitaxelapproved, vet_approvedPhase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
8Albumin-Bound PaclitaxelPhase 22864
9
Mentholapproved26062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
10Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate13
11Chelating Agents1423

Interventional clinical trials:

idNameStatusNCT IDPhase
1Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer PatientsUnknown statusNCT02078388Phase 2, Phase 3
299mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerActive, not recruitingNCT02677714Phase 2
3Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer PatientsCompletedNCT03000036
4Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via ChemotherapyRecruitingNCT02796365

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

About this section

Anatomical Context for Doxorubicin Induced Cardiomyopathy

About this section

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

36
Heart, Bone, Bone marrow, Pituitary, Testes, Myeloid

Publications for Doxorubicin Induced Cardiomyopathy

About this section

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50)    (show all 132)
idTitleAuthorsYear
1
Correction to: "Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. (28087848)
2017
2
Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. (27294099)
2016
3
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. (27087047)
2016
4
Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. (27261628)
2016
5
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. (27167338)
2016
6
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. (26873966)
2016
7
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. (25590792)
2015
8
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. (26057572)
2015
9
Shengmai injection improved Doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. (25839043)
2015
10
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. (26885153)
2015
11
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. (25660617)
2015
12
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. (26511374)
2015
13
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. (26191652)
2015
14
Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. (26075032)
2015
15
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. (25938766)
2015
16
Heart rate dynamics in doxorubicin-induced cardiomyopathy. (25798626)
2015
17
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. (25569804)
2015
18
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. (25504881)
2014
19
Embryonic Stem Cells and Released Factors Stimulate c-kit (+ve) /FLK-1(+ve) Progenitor Cells and Promote Neovascularization in Doxorubicin-induced Cardiomyopathy. (24593859)
2014
20
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. (24486195)
2014
21
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice. (25263201)
2014
22
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. (25298583)
2014
23
Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. (24767791)
2014
24
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. (23741376)
2013
25
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. (24334905)
2013
26
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. (24338479)
2013
27
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. (23731918)
2013
28
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. (24228260)
2013
29
Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats. (24343415)
2013
30
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. (24244825)
2013
31
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. (22449713)
2012
32
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (22465037)
2012
33
Effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy. (22244634)
2012
34
Discordant impairment of multidirectional myocardial deformation in rats with Doxorubicin induced cardiomyopathy. (22486544)
2012
35
Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. (22719160)
2012
36
Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. (22729889)
2012
37
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. (22808256)
2012
38
S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. (22039489)
2011
39
Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. (21330293)
2011
40
Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. (22110719)
2011
41
Bovine model of doxorubicin-induced cardiomyopathy. (21253525)
2011
42
Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? (21596235)
2011
43
Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. (21946105)
2011
44
Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. (21624372)
2011
45
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. (21094500)
2011
46
Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. (21596234)
2011
47
Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. (20978005)
2011
48
Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. (20101000)
2010
49
Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). (20668052)
2010
50
CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. (19942623)
2010

Variations for Doxorubicin Induced Cardiomyopathy

About this section

Expression for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section
Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
19.7GATA4, MAPK14
29.6EGFR, EPOR
39.5HGF, MET
49.4EGFR, MET
59.2GATA4, HGF, MET
69.1EGFR, HGF, MET
7
Show member pathways
9.1EGFR, HGF, MET
8
Show member pathways
9.1EGFR, HGF, MET
99.1EGFR, HGF, MET
109.1EGFR, HGF, MET
119.1EGFR, HGF, MET
129.0EGFR, EPHB2, MET
13
Show member pathways
9.0HGF, MAPK14, MET
148.8CSF3, HGF, MAPK14
15
Show member pathways
8.8EGFR, EPOR, GATA4, MAPK14
168.7CSF3, HGF, MET
178.6EGFR, HGF, MAPK14, MET
18
Show member pathways
8.6EGFR, HGF, MAPK14, MET
19
Show member pathways
8.5EGFR, EPOR, MAPK14, MET
20
Show member pathways
8.3EGFR, EPHB2, EPOR, HGF, MET
21
Show member pathways
8.2CNR1, EGFR, HGF, MAPK14, MET
22
Show member pathways
8.2EGFR, EPHB2, HGF, MAPK14, MET
23
Show member pathways
8.1EGFR, EPHB2, EPOR, MAPK14, MET
247.8CSF3, EGFR, EPOR, HGF, MET
25
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
26
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
27
Show member pathways
7.8EGFR, EPHB2, EPOR, HGF, MAPK14, MET
28
Show member pathways
7.5EGFR, EPHB2, EPOR, GATA4, HGF, MAPK14
29
Show member pathways
6.9CSF3, EGFR, EPHB2, EPOR, HGF, MAPK14
30
Show member pathways
6.6CSF3, DES, EGFR, EPHB2, EPOR, HGF
31
Show member pathways
6.4CSF3, ECE1, EGFR, EPHB2, EPOR, HGF

GO Terms for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055766.9CSF3, EGFR, EPHB2, EPOR, HGF, MAPK14

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1axonal fasciculationGO:000741310.5CNR1, EPHB2
2hepatocyte growth factor receptor signaling pathwayGO:004801210.3HGF, MET
3negative regulation of hydrogen peroxide-mediated programmed cell deathGO:190129910.3HGF, MET
4positive chemotaxisGO:005091810.3HGF, MET
5negative regulation of autophagyGO:001050710.0GATA4, HGF, MET
6phosphatidylinositol phosphorylationGO:00468549.8EGFR, HGF, MET
7phosphatidylinositol-mediated signalingGO:00480159.8EGFR, HGF, MET
8regulation of phosphatidylinositol 3-kinase signalingGO:00140669.6EGFR, HGF, MET
9cell morphogenesisGO:00009029.6EGFR, EPHB2, HGF, MAPK14
10peptidyl-tyrosine phosphorylationGO:00181089.4EGFR, EPHB2, HGF, MET
11MAPK cascadeGO:00001659.3EGFR, HGF, MAPK14, MET
12protein phosphorylationGO:00064689.1EGFR, EPHB2, MAPK14, MET
13transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.0EGFR, EPHB2, MET
14positive regulation of transcription from RNA polymerase II promoterGO:00459448.1CSF3, EGFR, GATA4, HGF, MAPK14, MET

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1NFAT protein bindingGO:005152510.4GATA4, MAPK14
2phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:00469349.8EGFR, HGF, MET
3Ras guanyl-nucleotide exchange factor activityGO:00050889.5EGFR, HGF, MET
4protein phosphatase bindingGO:00199039.5EGFR, MAPK14, MET
5protein tyrosine kinase activityGO:00047139.3EGFR, EPHB2, HGF, MET
6protein kinase activityGO:00046729.1EGFR, EPHB2, MAPK14, MET
7transmembrane receptor protein tyrosine kinase activityGO:00047149.0EGFR, EPHB2, MET

Sources for Doxorubicin Induced Cardiomyopathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet